Search

Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies

BIOGEN, SANGAMO INK NEURO DEAL FOR NEW “GENE REGULATION” THERAPIES

Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially...

Passage Bio's IPO Raises $216M to Fund Gene Therapy Studies

PASSAGE BIO'S IPO RAISES $216M TO FUND GENE THERAPY STUDIES

Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million-72 percent more than it...

 
 
 
7 Brands That Petite, Plus-Size Women Will Love

7 BRANDS THAT PETITE, PLUS-SIZE WOMEN WILL LOVE

Yes, sometimes shopping is fun and can provide some much-needed retail therapy, but everyone knows that shopping can also occasionally...

Esperion's Combo Pill for Lowering Cholesterol Levels Wins FDA Nod

ESPERION'S COMBO PILL FOR LOWERING CHOLESTEROL LEVELS WINS FDA NOD

An Esperion Therapeutics drug that pairs two cholesterol-lowering medicines in a single pill has been approved by the FDA, the second...

 
 
 

TAKEDA PHARMACEUTICALS BUYS SAN DIEGO BIOTECH FOR $330M TO ENHANCE DRUG PIPELINE FOR CELIAC DISEASE

The buyout of PvP Biologics highlights the potential of a new therapy for severe gluten intolerance that affects 3 million Americans...

Field Trip raised $8.5 million to take psychedelic medicine mainstream. We got an exclusive look at the pitch deck that helped make it happen

FIELD TRIP RAISED $8.5 MILLION TO TAKE PSYCHEDELIC MEDICINE MAINSTREAM. WE GOT AN EXCLUSIVE LOOK AT THE PITCH DECK THAT HELPED MAKE IT HAPPEN

Field Trip Psychedelics raised $8.5 million to build out a network of clinics for psychedelic-assisted therapies. While the psychedelic...

 
 
 
Doctors Are Injecting This Naturally-Derived Substance to Restore Hair Thickness-and It's Not PRP

DOCTORS ARE INJECTING THIS NATURALLY-DERIVED SUBSTANCE TO RESTORE HAIR THICKNESS-AND IT'S NOT PRP

“The most emotional issue my patients have is hair loss ,” says New York dermatologist Cheryl Karcher, MD below a jaw-dropping before-and-after...

Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact

BICYCLE THERAPEUTICS LANDS $30M FROM GENENTECH IN NEW CANCER R&D PACT

Genentech is the latest company to enter a drug discovery partnership with Bicycle Therapeutics, adding a new alliance in cancer research...

 
 
 
Meet Rampart - GMR Therapy Dog in Training

MEET RAMPART - GMR THERAPY DOG IN TRAINING

UK Reveals Plans For ‘Dynamic' Post-Brexit Regulatory System

UK REVEALS PLANS FOR ‘DYNAMIC' POST-BREXIT REGULATORY SYSTEM

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation....

 
 
 
Hilaria Baldwin Says This In-Office Treatment ‘Changed Her Face' for the Better

HILARIA BALDWIN SAYS THIS IN-OFFICE TREATMENT ‘CHANGED HER FACE' FOR THE BETTER

Hilaria Baldwin needs a break. As a mother of four, cohost of podcast Mom Brain, cofounder of Yoga Vida, author of The Living Clearly...

VIKING THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ - Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development...

 
 
 
 
 
 

PLANT-BASED RELATIVES OF CHOLESTEROL COULD GIVE BOOST TO GENE THERAPY

Gene-infused nanoparticles used for combating disease work better when they include plant-based relatives of cholesterol because their...

RESEARCH TEAM TACKLES SUPERBUG INFECTIONS WITH NOVEL THERAPY

Superbug infections kill 35,000 people in the US annually. A team of researchers has found that a treatment known as AB569 kills pseudomonas...

 
 
 

AVEXIS INC.: SENIOR MANAGER, FINANCIAL PLANNING AND ANALYSIS

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated...

 
 
 
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal

SEAGEN ADDS FIVE PRIME THERAPEUTICS ANTIBODIES IN LICENSING DEAL

Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical...

FIRST PATIENT UNDERGOES LUXTURNA GENE THERAPY ON NHS

Posted on: 20 February 2020, The NHS has reported treating its first patient with Novartis' Luxturna a “revolutionary” new gene therapy...